• \- Subjects who meet all the following criteria can be included in this study：

• 1\. Newly diagnosed lymphoma or non-lymphoma patients (breast cancer, soft tissue sarcoma, etc.) as well as lymphoma or non-lymphoma patients that do not have a history of anthracycline treatment (doxorubicin, epirubicin, pyrandoxorubicin, daunorubicin, demethoxydaunorubicin, aclarithromycin, mitoxantrone, etc.)；Cancer patients should meet the following requirements:

• Lymphoma：

‣ Lymphoma patients confirmed by histopathology；

⁃ No previous history of anthracyclines treatment；

⁃ Doxorubicin treatment planned for no less than 6 cycles；

• Non-lymphoma (breast cancer, soft tissue sarcoma, etc.)：

‣ Subjects with malignant tumors (breast cancer, soft tissue sarcoma, etc.) confirmed by histopathology and/or cytology；

⁃ Subjects planned to be treated with doxorubicin continuously for no less than 4 cycles（The cumulative dose of doxorubicin is no less than 240 mg/m2.）；

⁃ Subjects with no history of systemic chemotherapy involving anthracyclines； 2.Age 18-75 years old, male or female； 3.ECOG PS score 0-1； 4.Expected survival ≥24 weeks； 5. Vital organs function well, that is, relevant examination indicators within 14 days before randomization meet the following requirements：

• <!-- -->

• Blood routine tests：

‣ Hemoglobin ≥95 g/L (no blood transfusion within 14 days)；

⁃ Neutrophil count ≥1.5×109/L；

⁃ Platelet count ≥75×109/L；

• Blood biochemical tests：

‣ Total bilirubin ≤ 1.5×ULN ( upper limit of normal )；

⁃ Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 3.0×ULN；

⁃ Creatinine (Cr) ≤1.5×ULN or creatinine clearance rate ≥ 60 ml/min (CockcroftGault formula)； 6.Male or female patients of childbearing potential who are willing to use effective contraceptive methods during the study, as well as within 6 months after the last dose of treatment (e.g., double barrier, condoms, oral or injectable contraceptives, intrauterine devices, etc.). All female patients will be considered to be of childbearing potential unless the female patient has undergone natural menopause, artificial menopause or sterilization (such as hysterectomy, bilateral adnexectomy or radioactive ovarian irradiation, etc.).The serum test results within 7 days prior to the enrollment of female patients must show that they are not pregnant , and they must be non-lactating.

∙ Subjects'participation should be voluntary，subjects have signed the informed consent form，show good compliance, and are able to actively cooperate with treatment and follow-up visits.